AzTrials
AzTrials

NeurologyNCT01212419

SWC on aEEG in Post-surgical Neonates on Morphine and Midazolam

An observational study of Neurology and Newborn, run by Royal Children's Hospital.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objectives: Sleep characteristics have been used for prediction of neuro-developmental outcome. The aim of our study was to evaluate the influence of morphine and midazolam on the development of SWC in newborns > 32 weeks' gestational age after major non-cardiac surgery. Read more about this study

Who is it for?
Ages 32 to 50 weeks
Conditions the study is for
Neurology, Newborn, Analgesia
How many people
47 participants
Where
No sites listed yet
Study dates
Mar 2009to Dec 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 32 to 50 weeks
  • All sexes
  • No healthy volunteers
  • Child

Study population: newborns > 32 weeks' gestational age post abdominal surgery

Who may be able to join

  • > 32 weeks' gestational age
  • abdominal surgery

Who cannot join

  • < 32 weeks' gestational age
  • neurologically compromised

About this study

Official title: Effects of Morphine and Midazolam on Sleep-wake Cycling in Amplitude-integrated Electroencephalography in Post-surgical Neonates > 32 Weeks' Gestational Age

Objectives: Sleep characteristics have been used for prediction of neuro-developmental outcome. The aim of our study was to evaluate the influence of morphine and midazolam on the development of SWC in newborns > 32 weeks' gestational age after major non-cardiac surgery.

Study design: This prospective aEEG study included infants > 32+0 weeks' gestation admitted to the Neonatal Intensive Care Unit at The Royal Children's Hospital in Melbourne who were undergoing major non-cardiac surgery. The BrainZ Monitor (BRM2, Version 8.0, BrainZ Instruments, New Zealand) was applied post-operatively. The time of onset and quality of SWC and the maximum levels of morphine and midazolam as predictors of time to SWC were then assessed.

Read more

Results: Forty-seven eligible infants were included. Emergence of SWC was observed at a mean of 13 hours post-surgery. The maximum dose of morphine or midazolam was not predictive of time to SWC.

Conclusions: Despite high doses of continuous infusions of morphine and midazolam SWC was observed on aEEG in neonates > 32 weeks' gestational age soon after major non-cardiac surgery. The main type of aEEG background pattern was not affected by the maximum dose of either morphine or midazolam. Abnormalities in aEEG in post-surgical patients are not always drug related.

Read the detailed description

There is increasing evidence of neurodevelopmental impairment in survivors of non-cardiac surgery (1,2,3,4). Psychosocial maldevelopment and emotional problems have been reported to occur more commonly in children with repaired abdominal wall defects, and routine assessment of survivors of non-cardiac surgery has been recommended throughout later childhood (5,6). These reports also emphasize the need for further study of children who undergo major non-cardiac surgery in the neonatal period so that the neurological substrate for subsequent abnormal neurodevelopment can be better understood.

Amplitude-integrated electroencephalography (aEEG) is being increasingly used to monitor cerebral activity at the bedside in the neonatal intensive care unit (NICU) (7). Widely used scoring systems for aEEG incorporate consideration of background activity, presence of sleep wake cycling (SWC) and seizures (8). There are several aEEG reports indicating that analgesic and sedative agents routinely used in neonates suppress amplitude and therefore alter background activity (9,10,11,12,13) and it is believed that interpretation of aEEG in sedated patients is unreliable. Most of these studies have been conducted investigating pre-term infants or infants with hypoxic-ischaemic encephalopathy.

Sleep characteristics have been reported as predictors of neurodevelopmental outcome (14,15,16) and there is general agreement that indices of stability in SWC over time are positively correlated with improved clinical outcomes. SWC is described as smooth sinusoidal variations, mostly in the minimum amplitude. Phases with broader bandwidth represent discontinuous background activity during quiet sleep, whilst the phases with narrower bandwidth correspond to the more continuous activity during wakefulness and active sleep. SWC develops with increasing maturation of the child. From 31 to 32 weeks' gestational age, quiet sleep periods are clearly discernable in the aEEG trace as distinct periods with increased bandwidth. At term-equivalent age these periods represent trace alternant electroencephalography (EEG) patterns (17). The average duration of quiet sleep periods is 24 to 28 minutes for infants between 32 and 36 weeks' gestational age. These periods are slightly longer at night but are otherwise relatively stable and are not affected by incubator covers or developmental care interventions (18). The internal trigger for SWC is located in the brainstem and the presence of SWC in healthy term newborns is considered a sign of brain stem integrity (19,20). In newborns with hypoxic-ischemic encephalopathy sleep organization can be altered and the presence of SWC on aEEG is considered to be a good prognostic sign (21). Timing of onset of SWC has been shown to predict neurodevelopmental outcome based on whether the SWC returns before or after 36 hours of a presumed hypoxic insult (22).

There are several reports indicating that analgesic and sedative agents routinely used in neonates may lead to amplitude depression on aEEG. However, to our knowledge there are currently no reports of aEEG studies and SWC in newborn infants requiring major non-cardiac surgery during the neonatal period. Studying background activity and emergence of SWC on aEEG in neonates requiring major non-cardiac surgery may provide useful information about the relationship of analgesia and sedation and cerebral function in the post-operative infant. Knowledge of the effects of drugs that may modify cerebral activity is important to the interpretation of aEEG's in critically ill neonates requiring high doses of analgesics and sedatives.

The aim of this prospective observational aEEG study was to describe the influence of analgesic and sedative medication on background pattern and the development of SWC in newborn infants born > 32 weeks' gestation after major non-cardiac surgery.

Medical subject headings
Agnosia

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Sep 2010 (estimated)
  2. Study startMar 2009
  3. Primary completionDec 2009
  4. Study completionDec 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
47 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01212419
Sponsor's protocol ID
HREC #28122
Status last verified
Sep 2010
First submitted
29 Sep 2010
Last updated
1 Oct 2010
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Neurology and Newborn, run by Royal Children's Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Oct 2010. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in